Benefits
Supports healthy liver fat markers in overweight adults
In a 12-week placebo-controlled trial of 90 overweight, non-drinking adults with intermediate Fatty Liver Index scores (31 to 59), 300 mg a day lowered the index by about 14% from baseline, while it rose about 8% on placebo. The index is calculated from triglycerides, GGT, BMI and waist size; liver fat itself was not measured as an outcome. It is a single, company-funded trial.
Liver blood tests (GGT, ALT, AST, ALP) lower than placebo
Everyone in the trial started with liver tests in the normal range. After 84 days GGT, ALT, AST and ALP were lower on 4Liver than on placebo, and GGT fell about 20% from baseline. Part of the gap came from placebo values drifting upward. These are shifts within the normal range, shown in a single trial.
Raised blood glutathione and lowered lipid peroxidation markers
In the same single trial, serum glutathione rose about 44% and superoxide dismutase about 34% versus placebo, while malondialdehyde, a lipid peroxidation marker, fell about 23% versus placebo. These are blood markers of antioxidant status; the trial did not measure removal of any toxin.
Lower triglycerides and cholesterol than placebo
After 84 days triglycerides were about 15% and total cholesterol about 10% lower than placebo, and LDL cholesterol fell about 16% from baseline. Silymarin lowered LDL and total cholesterol from baseline in the same trial. People taking cholesterol medicine were excluded, and the result comes from a single trial.
Better quality-of-life and digestive comfort scores
On the SF-36 questionnaire, physical functioning improved about 20% more than placebo, and vitality and several other domains improved from baseline. The total digestive symptom score fell about 43% versus placebo. Silymarin improved similar scores. These were secondary outcomes in a single trial.
Compared with silymarin in the same trial
The trial included a 320 mg silymarin (milk thistle) arm. Against placebo the index fell about 16% with 4Liver and about 7% with silymarin, but the paper reported no statistical comparison between the two products, and the authors described their effects on the other markers as comparable.
Mechanism of action
Antioxidant polyphenols
Both herbs are rich in polyphenols such as gallic acid, ellagic acid and chebulic ellagitannins. In mice given a liver toxin, a Terminalia chebula water extract limited the rise in liver enzymes and restored glutathione and antioxidant enzymes. In people, the blend raised serum glutathione and superoxide dismutase and lowered malondialdehyde.
Calming inflammatory signals in the liver
In the same mouse study, Terminalia chebula pretreatment blunted the rise in the inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in liver tissue. Inflammatory markers were not measured in the human trial, so this remains an animal finding.
Fat and sugar handling
In the human trial triglycerides, cholesterol and the insulin resistance score HOMA-IR fell, which fits an effect on how the liver handles fat and sugar. The mechanism behind this was not studied directly.
Clinical trials
Randomized, double-blind, placebo-controlled 84-day trial with three arms: 300 mg CL16049F1, 320 mg silymarin or placebo, registered as CTRI/2020/05/025322. Funded by Chemiloids Life Sciences, which also manufactured the test product; the paper is not indexed in PubMed (Rajendra et al. 2022, Functional Foods in Health and Disease).
90 non-drinking, non-smoking overweight adults aged 25 to 60 (BMI 23 to 29) with Fatty Liver Index scores of 31 to 59 and normal liver blood tests; people with liver abnormalities on ultrasound, diabetes or medicine for chronic disease were excluded. 88 completed.
The primary outcome, Fatty Liver Index, fell 13.8% from baseline on CL16049F1 and was 16.1% lower than placebo at day 84; silymarin lowered it 7.5% from baseline. GGT, ALT, AST, ALP, triglycerides and total cholesterol were lower than placebo, serum glutathione and superoxide dismutase rose, and malondialdehyde fell. SF-36 and digestive symptom scores improved. Mild fatigue and bloating were reported, with no serious adverse events. The paper reported no statistical comparison of the two active products.